Rifabutin
- Generic Name
- Rifabutin
- Brand Names
- Mycobutin, Talicia
- Drug Type
- Small Molecule
- Chemical Formula
- C46H62N4O11
- CAS Number
- 72559-06-9
- Unique Ingredient Identifier
- 1W306TDA6S
- Background
A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients.
- Indication
For the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection.
- Associated Conditions
- Helicobacter Pylori Infection, Mycobacterium avium complex infection, Tuberculosis (TB), Late phase Tuberculosis
- Associated Therapies
- -
A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects
- First Posted Date
- 2008-08-28
- Last Posted Date
- 2010-11-02
- Lead Sponsor
- Abbott
- Target Recruit Count
- 15
- Registration Number
- NCT00743470
- Locations
- 🇺🇸
Site Reference ID/Investigator# 11441, Waukegan, Illinois, United States
Drug Interaction Study
- Conditions
- Interventions
- First Posted Date
- 2008-03-31
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 85
- Registration Number
- NCT00646776
- Locations
- 🇺🇸
Bristol-Myers Squibb Clinical Pharmacology Unit, Hamilton, New Jersey, United States
TBTC Study 23C: Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz
- Conditions
- First Posted Date
- 2001-09-10
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 20
- Registration Number
- NCT00023413
- Locations
- 🇺🇸
Chicago VA Medical Center (Lakeside), Chicago, Illinois, United States
🇺🇸Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TB
- Conditions
- First Posted Date
- 2001-09-10
- Last Posted Date
- 2005-09-13
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 150
- Registration Number
- NCT00023348
- Locations
- 🇺🇸
Denver Department of Public Health and Hospitals, Denver, Colorado, United States
🇺🇸Hines VA Medical Center, Hines, Illinois, United States
🇨🇦University of Manitoba, Winnipeg, Manitoba, Canada
TBTC Study 23B:Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB
- Conditions
- First Posted Date
- 2001-09-10
- Last Posted Date
- 2005-09-05
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 20
- Registration Number
- NCT00023400
- Locations
- 🇨🇦
University of British Columbia, Vancouver, British Columbia, Canada
🇺🇸LA County/USC Medical Center, Los Angeles, California, United States
🇺🇸Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen
- Conditions
- First Posted Date
- 2001-09-10
- Last Posted Date
- 2005-09-05
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 215
- Registration Number
- NCT00023361
- Locations
- 🇺🇸
Seattle King County Health Department, Seattle, Washington, United States
🇺🇸LA County/USC Medical Center, Los Angeles, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 246
- Registration Number
- NCT00001058
- Locations
- 🇺🇸
Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis, Indiana, United States
🇺🇸Methodist Hosp. of Indiana, Indianapolis, Indiana, United States
🇺🇸Harbor-UCLA Med. Ctr. CRS, Torrance, California, United States
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pharmacia
- Target Recruit Count
- 750
- Registration Number
- NCT00002267
- Locations
- 🇺🇸
East Bay AIDS Ctr, Berkeley, California, United States
🇺🇸AIDS Community Research Consortium, Redwood City, California, United States
🇺🇸Northwestern Univ Med School, Chicago, Illinois, United States
A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pharmacia
- Target Recruit Count
- 450
- Registration Number
- NCT00002101
- Locations
- 🇺🇸
TheraFirst Med Ctrs Inc, Fort Lauderdale, Florida, United States
🇺🇸Dr Frank Tornaka, Fort Lauderdale, Florida, United States
🇺🇸Gary Richmond MD, Fort Lauderdale, Florida, United States
A Double-Blind Randomized Clinical Trial of a Rifabutin Regimen in the Treatment of Mycobacterium-Avium Complex (MAC) Bacteremia in Patients With AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pharmacia
- Target Recruit Count
- 200
- Registration Number
- NCT00001995
- Locations
- 🇺🇸
AIDS Community Research Consortium, Redwood City, California, United States
🇺🇸Mem Hosp Hollywood, Hollywood, Florida, United States
🇺🇸Infectious Disease Research Consortium of Georgia, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.